Vertex Pharmaceuticals has a virtual monopoly in treating cystic fibrosis, having created and brought to market a function cure for 90% of the CF population. Their pipeline outside of CF has shown ...

Vertex's diverse pipeline, including Casgevy for SCD, suzetrigine for chronic pain, and the vanzacaftor triple for CF, positions it for growth despite launch challenges. Casgevy's complex ...

Jessica Fye has given her Buy rating due to a combination of factors that highlight Vertex Pharmaceuticals’ promising developments, particularly concerning their drug suzetrigine. The recent ...

A recent s urvey conducted nationwide by Vertex Pharmaceuticals asked 1,001 patients who were affected by moderate-to-severe acute pain in the last year and 547 health care providers who treated ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $478.09, reflecting a -1.02% shift from the previouse trading day's closing. This change lagged the S&P 500's 0 ...

Investors in Vertex Pharmaceuticals, Inc. (Symbol: VRTX) saw new options begin trading today, for the November 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Vertex Pharmaceuticals fair value estimate is US$855 Current... BOSTON, October 18, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq ...